Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry
Authors' conclusion
Nationwide real-world data showed that tofacitinib therapy is effective in patients with RA independent of previous use of a bDMARD. The drug retention of tofacitinib did not differ between bDMARD-failure and -naive patients, and RF or ACPA positivity may be associated with reduced discontinuation of tofacitinib.
Study context
- Population
- Patients with rheumatoid arthritis (RA) receiving tofacitinib in the Korean College of Rheumatology Biologics and Targeted Therapy registry (16.3% male; mean age 55.4±11.9 years)
- Participants
- 300 patients
- Exposure
- Tofacitinib in biologic disease-modifying anti-rheumatic drug (bDMARD)-failure vs bDMARD-naive patients with RA
- bDMARD-naiven = 91reference
- Outcome
- Drug retention of tofacitinib
Methodological detailsnationwide registry, real-world data
- Nationwide registry
- Real-world data
Main finding
As reported in the abstract
bDMARD-failure
155 per 2.4 years
bDMARD-naive
89 per 1.9 years
Log-rank test, p=0.202
Observational data: associations, not effects.
Further findings
ACR responses and DAS28 · 1-year follow-up
- Did not differ between bDMARD-failure and -naive patients
Predictors of reduced drug retention (logistic regression)
- RF positivity associated with reduced drug retention
- P = 0.01
- ACPA positivity associated with reduced drug retention
- 0.02
Safety
Adverse events (whole cohort)
- Patients with adverse events
- 83 (27.7%)
Herpes zoster infection (whole cohort)
- Patients with herpes zoster infection
- 14 (4.7%)
Original publication
Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry. Clin Exp Rheumatol. Published 21 March 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →